BeiGene EPS - Earnings per Share 2014-2024 | BGNE

BeiGene earnings per share (EPS) for the twelve months ending September 30, 2024 was $-8.19, a 11.56% decline year-over-year.

  • BeiGene EPS for the quarter ending September 30, 2024 was $-1.15, a 157.21% decline year-over-year.
  • BeiGene 2023 annual EPS was $-8.45, a 56.51% decline from 2022.
  • BeiGene 2022 annual EPS was $-19.43, a 23.68% increase from 2021.
  • BeiGene 2021 annual EPS was $-15.71, a 17.88% decline from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.

BeiGene EPS - Earnings per Share 2014-2024 | BGNE

  • BeiGene EPS for the quarter ending September 30, 2024 was $-1.15, a 157.21% decline year-over-year.
  • BeiGene 2023 annual EPS was $-8.45, a 56.51% decline from 2022.
  • BeiGene 2022 annual EPS was $-19.43, a 23.68% increase from 2021.
  • BeiGene 2021 annual EPS was $-15.71, a 17.88% decline from 2020.

Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$150.5B
Bristol Myers Squibb (BMY)$118.1B
Vertex Pharmaceuticals (VRTX)$115.4B
Gilead Sciences (GILD)$109.4B
CSL (CSLLY)$85.4B
Regeneron Pharmaceuticals (REGN)$81.8B
GSK (GSK)$69.3B
Argenex SE (ARGX)$34.4B
Alnylam Pharmaceuticals (ALNY)$30.2B
BioNTech SE (BNTX)$25.5B
Biogen (BIIB)$22.6B
Illumina (ILMN)$21.4B
Moderna (MRNA)$14.3B
Incyte (INCY)$13.6B
Genmab (GMAB)$13.6B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.8B
Vaxcyte (PCVX)$10.9B
Bio-Techne Corp (TECH)$10.5B
Sarepta Therapeutics (SRPT)$10.2B
Exact Sciences (EXAS)$10B
Exelixis (EXEL)$9.8B
Revolution Medicines (RVMD)$9.5B
Bio-Rad Laboratories (BIO.B)$9.4B
QIAGEN (QGEN)$9.3B
Intra-Cellular Therapies (ITCI)$8.8B
Roivant Sciences (ROIV)$8.4B
Ascendis Pharma (ASND)$7.5B
Repligen (RGEN)$7.2B
Legend Biotech (LEGN)$7B